These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 97826)

  • 41. Effector mechanisms of cell-mediated immunity to xenogeneic cell antigens.
    Dennert G
    J Immunol; 1974 Jul; 113(1):201-8. PubMed ID: 4208918
    [No Abstract]   [Full Text] [Related]  

  • 42. Allograft cytotoxicity. Two populations of effector cell detectable by cytolytic and cytostatic assays in vitro.
    Jones B; Jones TC; Roitt IM
    Immunology; 1977 Apr; 32(4):591-9. PubMed ID: 415967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge.
    Niederkorn JY; Streilein JW
    J Immunol; 1983 Nov; 131(5):2587-94. PubMed ID: 6415174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanism of cytolysis by thymus-derived lymphocytes. Implications in tumor immunity.
    Henney CS
    Prog Exp Tumor Res; 1974; 19():203-16. PubMed ID: 4373780
    [No Abstract]   [Full Text] [Related]  

  • 45. Discussion paper: the immune status of the murine host bearing transplantable syngeneic growing tumors.
    Manson LA
    Ann N Y Acad Sci; 1976; 276():272-5. PubMed ID: 829206
    [No Abstract]   [Full Text] [Related]  

  • 46. Diminished cellular cytotoxicity in mice hyperimmunized prior to skin grafting.
    Sugarbaker PH
    Cell Immunol; 1981 Jan; 57(1):99-113. PubMed ID: 6783318
    [No Abstract]   [Full Text] [Related]  

  • 47. Suppression of cell-mediated immunity to challenge with P 815 mastocytoma in concanavalin A-treated mice.
    Ekstedt RD; Merdian DJ
    Cell Immunol; 1983 Jan; 75(1):181-7. PubMed ID: 6297806
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Augmentation of antigen-specific cytotoxicity by concanavalin A at the peak of response to tumor allografts.
    Shimamoto Y; Nomoto K; Taniguchi K; Kubo C
    Cell Immunol; 1979 Sep; 47(1):204-10. PubMed ID: 92366
    [No Abstract]   [Full Text] [Related]  

  • 49. Studies on the induction and expression of T cell-mediated immunity. XI. Inhibition of the "lethal hit" in T cell-mediated cytotoxicity by heterologous rat antiserum made against alloimmune cytotoxic T lymphocytes.
    Hiserodt JC; Bonavida B
    J Immunol; 1981 Jan; 126(1):256-62. PubMed ID: 6161164
    [No Abstract]   [Full Text] [Related]  

  • 50. Cell-mediated cytostasis: a critical analysis of methodological problems.
    Gyöngyössy MI; Liabeuf A; Golstein P
    Cell Immunol; 1979 Jun; 45(1):1-14. PubMed ID: 110465
    [No Abstract]   [Full Text] [Related]  

  • 51. Suppressor factor from tumor-allosensitized spleen cells--its effect on in vitro proliferation of tumor cells and in vivo skin allograft survival.
    Argyris BF
    Cell Immunol; 1981 Jan; 57(1):62-72. PubMed ID: 6452215
    [No Abstract]   [Full Text] [Related]  

  • 52. Involvement of peritoneal macrophages in cellular responses to mastocytoma in resistant and susceptible mice.
    Farber P; Specter S; Friedman H
    Adv Exp Med Biol; 1979; 121B():521-30. PubMed ID: 121034
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low numbers of tumor cells suppress the host immune system.
    Kölsch E; Mengersen R
    Adv Exp Med Biol; 1976; 66():431-6. PubMed ID: 817574
    [No Abstract]   [Full Text] [Related]  

  • 54. Variations in the intensity of BCG-potentiated alloimmune anti-tumor responses: the differential stimulation of T-cell subpopulations.
    Davies M; Sabbadini E; Kendall L
    Immunobiology; 1981; 160(3-4):311-20. PubMed ID: 6799388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rejection of allogeneic tumor cells growing in mouse cerebrospinal fluid. Functional analysis of the inflammatory process.
    Doherty PC; Zinkernagel RM; Ramshaw IA; Grant CK
    J Neuroimmunol; 1981 Mar; 1(1):93-9. PubMed ID: 6799545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early steps in specific tumor cell lysis by sensitized mouse T lymphocytes. V. Evidence that manganese inhibits a calcium-dependent step in programming for lysis.
    Gately MK; Martz E
    Cell Immunol; 1981 Jun; 61(1):78-89. PubMed ID: 6167369
    [No Abstract]   [Full Text] [Related]  

  • 57. Cytotoxic T cell responses to a syngeneic tumour: conditions for primary activation in vitro and biological activity in vivo.
    Warren HS; Woolnough JA; Denaro CP; Lafferty KJ
    Adv Exp Med Biol; 1979; 114():757-61. PubMed ID: 111489
    [No Abstract]   [Full Text] [Related]  

  • 58. Modification of mouse immune responses against allogeneic tumor by pretreatment of antigen with mitomycin C or X-irradiation.
    Hoffmann CC; Ehrke MJ; Papp G; Mihich E
    J Immunopharmacol; 1980; 2(2):213-23. PubMed ID: 6821578
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ability of tumor cells to resist humoral vs. cell-mediated immune attack is controlled by different membrane physical properties.
    Schlager SI
    Biochem Biophys Res Commun; 1982 May; 106(1):58-64. PubMed ID: 6809001
    [No Abstract]   [Full Text] [Related]  

  • 60. Low dose tolerance preventing tumor immunity.
    Kölsch E; Mengersen R; Diller E
    Eur J Cancer (1965); 1973; 9(11-12):879-82. PubMed ID: 4216506
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.